2,454 followers
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. #lymphoma #lymsm https://t.co/Tr2wxW1J0P
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. #lymphoma #lymsm https://t.co/Tr2wxW1J0P
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. #lymphoma #lymsm https://t.co/Yl79FIeJbx